This Article Figures Only Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (8) Citing Articles via Google Scholar Google Scholar Articles by Krötz, F. Articles by Sohn, H.-Y. Search for Related Content PubMed PubMed Citation Articles by Krötz, F. Articles by Sohn, H.-Y.

The Tyrosine Phosphatase, SHP-1, Is a Negative Regulator of Endothelial Superoxide Formation

Florian Krötz, MD^_*,,_*, Barbara Engelbrecht, MS^_*, Martin A. Buerkle, MD, Florian Bassermann, MD, Hanna Bridell, BS^_*, Torsten Gloe, PhD^_*, Justus Duyster, MD, Ulrich Pohl, MD^_* and Hae-Young Sohn, MD

^_* Institute of Physiology, Ludwig-Maximilians University, Munich, Germany
Institute of Cardiology, Medical Policlinic, Ludwig-Maximilians University, Munich, Germany
Clinic of Anesthesiology, Ludwig-Maximilians University, Munich, Germany
Department of Internal Medicine III, TU Munich, Germany

Manuscript received August 21, 2004; revised manuscript received January 4, 2005, accepted February 1, 2005.

^_* Reprint requests and correspondence: Dr. Florian Krötz, Cardiology, Medical Policlinic, Ludwig-Maximilians-University, Ziemssenstr. 1, 80336 Munich, Germany. (Email: fkroetz{at}lmu.de).

OBJECTIVES: We investigated the role of SH2-domain containing phosphatase-1 (SHP-1) in endothelial reduced nicotinamide adenine dinucleotide (phosphate) (NAD[P]H)-oxidase-dependent oxidant production.

BACKGROUND: Superoxide (O₂^·–) generation by endothelial NAD(P)H-oxidase promotes endothelial dysfunction and atherosclerosis. Signaling pathways that regulate NAD(P)H-oxidase activity are, however, poorly understood.

METHODS: SH2-domain containing phosphatase-1 was inhibited using site-directed magnetofection of antisense oligodesoxynucleotides (AS-ODN) or short interfering ribonucleic acid (siRNA) in vitro in human umbilical vein endothelial cells (HUVEC) and in isolated hamster arteries; O₂^·– was measured by cytochrome c reduction in vitro. Activities of NAD(P)H-oxidase activity, phosphatidyl-inositol-3-kinase (PI3K), and SHP-1 were assessed by specific assays; Rac1 activation was assessed by a pull-down assay.

RESULTS: Basal endothelial O₂^·– release was enhanced after inhibition of endothelial SHP-1 (p < 0.01), which could be prevented by specific inhibition of NAD(P)H-oxidase (p < 0.01); SHP-1 activity was high under basal conditions, further increased by vascular endothelial growth factor (10 ng/ml, p < 0.05), and abolished by SHP-1 AS-ODN treatment (p < 0.01), which also increased NAD(P)H-oxidase activity 3.3-fold (p < 0.01). Vascular endothelial growth factor also induced O₂^·– release (p < 0.01), which was even more enhanced when SHP-1 was knocked down (p < 0.05). The effect of SHP-1 was mediated by inhibition of PI3K/Rac1-dependent NAD(P)H-oxidase activation (p < 0.01); SHP-1 AS-ODN augmented tyrosine phosphorylation of the p85 regulatory subunit of PI3K (p < 0.05) and Rac1 activation. The latter was prevented by wortmannin, a blocker of PI3K.

CONCLUSIONS: In HUVEC, SHP-1 counteracts basal and stimulated NAD(P)H-oxidase activity by negative regulation of PI3K-dependent Rac1 activation; SHP-1 thus seems to be an important part of endothelial antioxidative defense controlling the activity of the O₂^·–-producing NAD(P)H-oxidase.

Abbreviations and Acronyms   AS-ODN = antisense oligodesoxynucleotide   HUVEC = human umbilical vein endothelial cells   NAD(P)H = reduced nicotinamide adenine dinucleotide (phosphate)   O2·– = superoxide radical   PI3K = phosphatidyl-inositol-3-kinase   PTP = protein tyrosine phosphatase   AT = angiotensin   RIPA = radioimmunoprecipitation (buffer)   SHP-1 = SH2-domain containing tyrosine phosphatase-1   siRNA = short interfering ribonucleic acid   SS = sodium stibogluconate

This article has been cited by other articles:

				Y. S. Cho, S. Y. Oh, and Z. Zhu Tyrosine Phosphatase SHP-1 in Oxidative Stress and Development of Allergic Airway Inflammation Am. J. Respir. Cell Mol. Biol., October 1, 2008; 39(4): 412 - 419. [Abstract] [Full Text] [PDF]

				A. Jabs, S. Gobel, P. Wenzel, A. L. Kleschyov, M. Hortmann, M. Oelze, A. Daiber, and T. Munzel Sirolimus-induced vascular dysfunction increased mitochondrial and nicotinamide adenosine dinucleotide phosphate oxidase-dependent superoxide production and decreased vascular nitric oxide formation. J. Am. Coll. Cardiol., June 3, 2008; 51(22): 2130 - 2138. [Abstract] [Full Text] [PDF]

				M. Mogi, M. Iwai, and M. Horiuchi Emerging Concepts of Regulation of Angiotensin II Receptors: New Players and Targets for Traditional Receptors Arterioscler. Thromb. Vasc. Biol., December 1, 2007; 27(12): 2532 - 2539. [Abstract] [Full Text] [PDF]

				F. Krotz, H.-Y. Sohn, and H. Mannell Letter by Krotz et al Regarding Article, "Improvement of Peripheral Endothelial Dysfunction by Protein Tyrosine Phosphatase Inhibitors in Heart Failure" Circulation, June 26, 2007; 115(25): e648 - e648. [Full Text] [PDF]

				M. Vercauteren, E. Remy, C. Devaux, B. Dautreaux, J.-P. Henry, F. Bauer, P. Mulder, C. Thuillez, V. Richard, R. Hooft van Huijsduijnen, et al. Response to Letter Regarding Article, "Improvement of Peripheral Endothelial Dysfunction by Protein Tyrosine Phosphatase Inhibitors in Heart Failure" Circulation, June 26, 2007; 115(25): e649 - e649. [Full Text] [PDF]

				F. Krotz, M. Keller, S. Derflinger, H. Schmid, T. Gloe, F. Bassermann, J. Duyster, C. D. Cohen, C. Schuhmann, V. Klauss, et al. Mycophenolate Acid Inhibits Endothelial NAD(P)H Oxidase Activity and Superoxide Formation by a Rac1-Dependent Mechanism Hypertension, January 1, 2007; 49(1): 201 - 208. [Abstract] [Full Text] [PDF]